A new market study, titled “Allergic Conjunctivitis (AC) – Market Insights, Epidemiology and Market Forecast-2027”, has been featured on WiseGuyReports.
The report ‘Allergic Conjunctivitis (AC) – Market Insights, Epidemiology and Market Forecast-2027’ delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Allergic Conjunctivitis (AC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Allergic Conjunctivitis (AC) – Disease Understanding and Treatment Algorithm
The Allergic Conjunctivitis (AC) market report gives the thorough understanding of the Allergic Conjunctivitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Allergic Conjunctivitis in the US, Europe, and Japan.
Allergic Conjunctivitis Epidemiology
The Allergic Conjunctivitis (AC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases and sub-type specific prevalent cases) scenario of Allergic Conjunctivitis (AC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to research study, the total number of diagnosed prevalent population of Allergic Conjunctivitis (AC) was found to be 64,945,428, in the year 2016.
Allergic Conjunctivitis Drug Chapters
This segment of the Allergic Conjunctivitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, there are mainly eight therapeutic classes of drugs contributing towards the market size of AC – Decongestants/Antihistamines, Corticosteroids, Topical Histamines, Systemic Histamines, Mast cell stabilizers (MCS), Immunomodulators, Nonsteroidal anti-inflammatory drugs (NSAIDs) and Dual acting Antihistamines/Mast cell stabilizers. The approved (and their generic versions) as well as off-label &/or OTC (Over the counter) products are being used for the treatment of Allergic Conjunctivitis, belonging to these therapeutic classes only. Detailed chapter for upcoming therapies like OTX-DP (also known as dexamethasone insert) (Ocular Therapeutics), ADX-102 (Aldeyra Therapeutics), PRT2761 (Portola Pharmaceuticals) and Bilastine (Faes Farma) have been covered in the report.
Allergic Conjunctivitis Market Outlook
The Allergic Conjunctivitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Upcoming therapies such as Zerviate (Nicox Pharma; NDA approved in May 2017, launch planned in the fall season of 2018), ADX-102 (Aldeyra Therapeutics), PRT-2761 (ORA, Inc.), OTX-DP (Ocular Therapeutix, Inc), DE114A (Santen Pharma; Only in Japan) and Bilastine (Faes Farma) have the potential to create a significant positive shift in the Allergic Conjunctivitis market size.
According to research study, the market of Allergic Conjunctivitis in 7MM was found to be USD 1,582 million in 2016 and is expected to increase at a CAGR of XX% from 2016-2027.
Allergic Conjunctivitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Allergic Conjunctivitis Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Allergic Conjunctivitis Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Allergic Conjunctivitis Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving Allergic Conjunctivitis market
- Organize sales and marketing efforts by identifying the best opportunities for Allergic Conjunctivitis market
- To understand the future market competition in the Allergic Conjunctivitis market.
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)